Infliximab in a patient with refractory mucosal aphthosis

Efficacy of tumour necrosis factor‐α antagonists in aphthous ulceration: review of published individual patient data

“…A total of 16 cases from individual case reports or small case series in which details of an individual’s previous systemic therapy and use of subsequent adjunctive therapy along with a specific TNF‐α antagonist in the treatment of oral aphthous ulceration were identified (Table 1). 23–36 No reports in the treatment of HIV‐associated aphthous ulceration were identified. TNF‐α blockers with reported success in resolving aphthous ulceration were infliximab, 23–29 etanercept 30–33 and adalimumab 34–36 .…”

“… 23–36 No reports in the treatment of HIV‐associated aphthous ulceration were identified. TNF‐α blockers with reported success in resolving aphthous ulceration were infliximab, 23–29 etanercept 30–33 and adalimumab 34–36 . Responses were seen in aphthous ulceration as a feature of BD (in some where genital involvement also featured), 23–28,30 Crohn’s disease (CD) 29,34 and recurrent aphthous stomatitis (RAS) 33,35,36 .…”

“…TNF‐α blockers with reported success in resolving aphthous ulceration were infliximab, 23–29 etanercept 30–33 and adalimumab 34–36 . Responses were seen in aphthous ulceration as a feature of BD (in some where genital involvement also featured), 23–28,30 Crohn’s disease (CD) 29,34 and recurrent aphthous stomatitis (RAS) 33,35,36 . In all cases, prior to TNF‐α blockade, development and frequency of ulceration was considered resistant to a range of systemic therapies, or such treatment was discontinued as a result of adverse effects.…”

“…In four such cases, thalidomide had been successfully trialed but was discontinued as a result of peripheral neuropathy or other neuromuscular symptoms 24,30,33 . A TNF‐α blocker was the sole therapy in eight cases, 23,27–30,33,36 whereas a reduced concomitant systemic regimen was continued in others. Rapid ulcer resolution, within 4 weeks (but often far sooner) was seen in the great majority of cases, although one delayed response (after 6 months of infliximab) was reported 27 .…”

Efficacy and safety of TNF-α inhibitors in refractory primary complex aphthosis: a patient series and overview of the literature

“…In all three patients, therapy with either adalimumab or etanercept induced rapid resolution of aphthous ulcerations (10)(11)(12). In addition, the TNF-a inhibitors infliximab and etanercept have been used successfully as monotherapy in 12 patients with complex aphthosis as part of either BD or Crohn's disease (15)(16)(17)(18)(19)(20). In a double-blind, placebo-controlled trial with 40 BD patients, therapy with etanercept for 4 weeks induced reduction in aphthous ulcerations (21).…”